Generics BulletinTeva is aiming to build a long-acting injectable schizophrenia franchise worth between $1.5bn and $2bn in annual sales at its peak, bolstered by a high unmet need and poor adherence for oral medicatio
Generics BulletinAs the name of the event suggested, Teva’s 29 May Innovation & Strategy Day presentation focused chiefly on plans to expand its branded medicines business, including a roadmap to achieve $2.5bn in
Generics BulletinTeva has filled a gap in its non-US oncology portfolio after inking a license and supply agreement with Prestige BioPharma to commercialize the Singaporean firm’s Tuznue (trastuzumab) biosimilar to Ro
ScripBiopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra